Ryman Healthcare Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Naomi James
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.3yrs |
| Board average tenure | 1.7yrs |
Recent management updates
Recent updates
Is Ryman Healthcare Limited (NZSE:RYM) Trading At A 42% Discount?
Nov 25
Is Ryman Healthcare (NZSE:RYM) Weighed On By Its Debt Load?
Aug 16Are Investors Undervaluing Ryman Healthcare Limited (NZSE:RYM) By 47%?
Jul 12Ryman Healthcare's (NZSE:RYM) Soft Earnings Don't Show The Whole Picture
Jun 05Little Excitement Around Ryman Healthcare Limited's (NZSE:RYM) Earnings
May 21Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint A Concerning Picture
Apr 24Ryman Healthcare Limited's (NZSE:RYM) P/E Is On The Mark
Feb 08Here's Why Ryman Healthcare (NZSE:RYM) Has A Meaningful Debt Burden
Jan 07Capital Allocation Trends At Ryman Healthcare (NZSE:RYM) Aren't Ideal
Dec 20What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?
Sep 11Ryman Healthcare (NZSE:RYM) Has Debt But No Earnings; Should You Worry?
Jul 04Ryman Healthcare Limited (NZSE:RYM) Shares Could Be 24% Below Their Intrinsic Value Estimate
May 30Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?
Aug 26When Should You Buy Ryman Healthcare Limited (NZSE:RYM)?
May 04What Is Ryman Healthcare Limited's (NZSE:RYM) Share Price Doing?
Jan 08Investors Could Be Concerned With Ryman Healthcare's (NZSE:RYM) Returns On Capital
Oct 14Is It Too Late To Consider Buying Ryman Healthcare Limited (NZSE:RYM)?
Sep 14Is Ryman Healthcare (NZSE:RYM) Using Too Much Debt?
Aug 04Should You Think About Buying Ryman Healthcare Limited (NZSE:RYM) Now?
May 22Is Ryman Healthcare Limited (NZSE:RYM) A Good Fit For Your Dividend Portfolio?
Apr 17Should You Review Recent Insider Transactions At Ryman Healthcare Limited (NZSE:RYM)?
Mar 20Our Take On The Returns On Capital At Ryman Healthcare (NZSE:RYM)
Mar 07Do Institutions Own Ryman Healthcare Limited (NZSE:RYM) Shares?
Feb 23Returns On Capital At Ryman Healthcare (NZSE:RYM) Paint An Interesting Picture
Nov 23CEO
Naomi James (46 yo)
less than a year
Tenure
Ms. Naomi M. James, LLB (Hons), MLM, is Chief Executive Officer of Ryman Healthcare Limited from November 2024. She served as Chief Executive Officer at Channel Infrastructure NZ Limited (formerly known as...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.7yrs | NZ$221.67k | 0.0055% NZ$ 164.8k | |
| Chief Executive Officer | less than a year | no data | no data | |
| Chief Financial Officer | 1.3yrs | no data | no data | |
| Chief Transformation & Strategy Officer and COO | less than a year | no data | no data | |
| Chief Customer & Technology Officer | 4.3yrs | no data | no data | |
| Chief People & Safety Officer | 2.1yrs | no data | no data | |
| Chief Development & Property Officer | 3.8yrs | no data | no data |
1.3yrs
Average Tenure
Experienced Management: RYM's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 1.7yrs | NZ$221.67k | 0.0055% NZ$ 164.8k | |
| Advisor to the Board | 7.8yrs | NZ$2.73m | no data | |
| Independent Director | 1.3yrs | NZ$53.87k | 0.0043% NZ$ 128.6k | |
| Director | 1.1yrs | no data | 0.0015% NZ$ 43.7k | |
| Independent Director | less than a year | no data | 0.0060% NZ$ 178.0k | |
| Non Executive Independent Director | 1.7yrs | NZ$109.17k | 0.0015% NZ$ 45.5k | |
| Lead independent director | 5.3yrs | NZ$151.94k | 0.0046% NZ$ 138.5k | |
| Independent Director | 6.3yrs | NZ$161.91k | 0.0078% NZ$ 234.8k |
1.7yrs
Average Tenure
Experienced Board: RYM's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/01 20:15 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ryman Healthcare Limited is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Andrew Steele | Credit Suisse |
| Stephen Ridgewell | Deutsche Bank |
| Aaron Ibbotson | Forsyth Barr Group Ltd. |